MannKind Corporation MNKD
Super Investor & Insider
Nessuna transazione insider negli ultimi 6 mesi.
Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.
About
MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapies and devices for patients with cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid overload in heart and chronic kidney disease. Its key products include …
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees591
TickerMNKD
Statistics
Market Cap$1.21B
Revenue (TTM)$349.0M
Net Income$5.9M
Net Margin1.7%
EPS$-0.07
P/E193.49
P/S3.21
P/B-19.50
EV/EBITDA40.25
ROE-11.5%
Dividend Yield—
Price$3.92
Data: Twelve Data · Revenue = mcap / P/S